AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 215
- Registration Number
- NCT00278889
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
🇧🇪Ressearch Site, Brussels, Belgium
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00278941
- Locations
- 🇬🇧
Research Site, Reading, United Kingdom
Faslodex in McCune-Albright Syndrome
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00278915
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00274469
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver
Not Applicable
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00272727
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00272753
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Esomeprazole in PPI Failures - IMPROVE
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00272701
- Locations
- 🇸🇪
Research site, Balsta, Sweden
🇸🇪Research Site, Vasteras, Sweden
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2007-02-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT00272740
- Locations
- 🇨🇭
Research Site, St.Gallen, Switzerland
Trial of Iressa in Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00265070
- Locations
- 🇨🇦
Research Site, Montreal, Canada
Phase II Iressa & Carbo/Gem in NSCLC
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00264498
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath